Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NTRA 
Natera Inc (NTRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: NTRA (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $198.45
1 Year Target Price $198.45
| 12 | Strong Buy |
| 8 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 48.16% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 23.63B USD | Price to earnings Ratio - | 1Y Target Price 198.45 |
Price to earnings Ratio - | 1Y Target Price 198.45 | ||
Volume (30-day avg) 21 | Beta 1.68 | 52 Weeks Range 117.27 - 183.00 | Updated Date 09/16/2025 |
52 Weeks Range 117.27 - 183.00 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -12.89% | Operating Margin (TTM) -20.19% |
Management Effectiveness
Return on Assets (TTM) -11.21% | Return on Equity (TTM) -24.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22307817342 | Price to Sales(TTM) 12.03 |
Enterprise Value 22307817342 | Price to Sales(TTM) 12.03 | ||
Enterprise Value to Revenue 11.36 | Enterprise Value to EBITDA -26.8 | Shares Outstanding 137248000 | Shares Floating 132861657 |
Shares Outstanding 137248000 | Shares Floating 132861657 | ||
Percent Insiders 3.2 | Percent Institutions 96.35 |
Upturn AI SWOT
Natera Inc
Company Overview
History and Background
Natera Inc. was founded in 2003. It is a genetic testing company that focuses on non-invasive prenatal testing (NIPT), cancer screening, and organ health. The company has grown through technological innovation and strategic acquisitions to expand its testing portfolio.
Core Business Areas
- Women's Health: Offers non-invasive prenatal testing (NIPT) for chromosomal abnormalities, paternity testing, and products for preimplantation genetic testing (PGT).
- Oncology: Provides personalized cancer therapy selection, minimal residual disease (MRD) assessment, and cancer screening tests.
- Organ Health: Offers solutions for assessing organ health and rejection risk after transplantation.
Leadership and Structure
The CEO is Steve Chapman. The company operates with a functional structure, with divisions for R&D, Sales, Marketing, and Operations.
Top Products and Market Share
Key Offerings
- Panorama NIPT: A non-invasive prenatal test that screens for chromosomal abnormalities such as Down syndrome. Natera holds a significant market share in NIPT, competing with Illumina and other diagnostic companies. Market share is estimated at approximately 40% of the U.S. NIPT market in 2023. Key Competitors: Illumina (ILMN), Labcorp (LH), Quest Diagnostics (DGX).
- Signatera MRD: A personalized cancer test that detects minimal residual disease after cancer surgery or treatment. Signatera competes with Guardant Health and other liquid biopsy companies. Signatera's market share is growing rapidly, estimated at around 25% of the MRD testing market as of 2023. Key Competitors: Guardant Health (GH), Exact Sciences (EXAS), Adaptive Biotechnologies (ADPT).
- Prospera Organ Transplant Assessment: A test designed to assess organ health and detect rejection risk in transplant recipients. Competes with CareDx and other transplant diagnostics companies. Estimated market share is around 15% of the transplant rejection monitoring market. Key Competitors: CareDx (CDNA).
Market Dynamics
Industry Overview
The genetic testing industry is experiencing rapid growth, driven by technological advancements, increasing awareness, and demand for personalized medicine. This market is highly competitive and regulated.
Positioning
Natera is positioned as a leading innovator in non-invasive genetic testing, with a strong focus on women's health, oncology, and organ health. Its competitive advantage lies in its proprietary technology platform and comprehensive testing portfolio.
Total Addressable Market (TAM)
The TAM for genetic testing is estimated to be over $50 billion. Natera is targeting segments within this TAM, including NIPT, MRD testing, and transplant monitoring, with potential for expansion into new areas.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Comprehensive testing portfolio
- Strong market position in NIPT
- Growing presence in oncology and organ health
- Extensive patent portfolio
Weaknesses
- High operating expenses
- History of net losses
- Dependence on reimbursement approvals
- Competition from larger diagnostic companies
- Regulatory scrutiny
Opportunities
- Expanding into new markets and geographies
- Developing new genetic tests
- Acquiring complementary technologies
- Partnering with pharmaceutical companies
- Increasing adoption of personalized medicine
Threats
- Intense competition
- Price erosion
- Changes in reimbursement policies
- Regulatory hurdles
- Technological obsolescence
Competitors and Market Share
Key Competitors
- ILMN
- GH
- CDNA
Competitive Landscape
Natera faces competition from established diagnostic companies and emerging players in the genetic testing market. Its competitive advantage lies in its proprietary technology and comprehensive testing portfolio.
Major Acquisitions
GeneDx
- Year: 2023
- Acquisition Price (USD millions): 325
- Strategic Rationale: Expanded Natera's offerings in rare diseases and exome sequencing.
Growth Trajectory and Initiatives
Historical Growth: Natera has experienced rapid revenue growth, driven by increased adoption of its genetic tests.
Future Projections: Analysts project continued revenue growth for Natera, but profitability remains uncertain.
Recent Initiatives: Recent initiatives include expanding the Signatera MRD test, commercializing the Prospera test, and pursuing strategic partnerships.
Summary
Natera is a rapidly growing genetic testing company with a strong presence in NIPT and expanding into oncology and organ health. The company's revenue is growing and its proprietary technology is innovative. However, profitability remains a challenge, and competition is intense. Natera needs to manage its operating expenses and secure reimbursement approvals to achieve sustainable growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is dynamic and may change rapidly. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Natera Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2015-07-02 | CEO & Director Mr. Steven Leonard Chapman | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 4424 | Website https://www.natera.com |
Full time employees 4424 | Website https://www.natera.com | ||
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.